Ionis Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $943.7M | $705.1M | $787.6M | $587.4M | $810.5M | $729.3M | $1.12B | $599.7M |
| Cost of Revenue | $15.9M | $11.2M | $9.1M | $14.1M | $10.8M | $11.9M | $4.4M | $1.8M |
| Gross Profit | $927.8M | $693.9M | $778.5M | $573.3M | $799.6M | $717.3M | $1.12B | $597.9M |
| Gross Margin | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% |
| Operating Expenses | ||||||||
| Research & Development | $915.6M | $901.5M | $899.6M | — | $638.2M | $531.0M | $461.5M | $411.9M |
| SG&A Expense | $393.9M | $267.5M | $232.6M | $150.3M | $186.3M | $354.3M | $286.6M | $244.6M |
| Operating Income | $-381.7M | $-475.1M | $-353.7M | $-410.2M | $-30.2M | $-172.1M | $365.9M | $-61.4M |
| Operating Margin | -40.4% | -67.4% | -44.9% | -69.8% | -3.7% | -23.6% | 32.6% | -10.2% |
| Interest Expense | $17.3M | $17.0M | $12.7M | $8.1M | $9.3M | $9.5M | $12.4M | $44.8M |
| Pretax Income | $-379.6M | $-460.1M | $-334.0M | $-258.0M | $-29.1M | $-134.6M | $338.8M | $-76.2M |
| Income Tax Expense | $1.8M | $-6.2M | $32.3M | $11.7M | $-551.0K | $345.2M | $51.5M | $-291.1M |
| Net Income | $-381.4M | $-453.9M | $-366.3M | $-269.7M | $-28.6M | $-444.3M | $278.1M | $273.7M |
| Net Margin | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% | -60.9% | 24.8% | 45.6% |
| EPS (Basic) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $2.00 | $2.09 |
| EPS (Diluted) | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $1.90 | $2.07 |
| Shares Outstanding (Basic) | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M | 139.6M | 140.0M | 132.3M |
| Shares Outstanding (Diluted) | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M | 139.6M | 153.2M | 134.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |